AllianceBernstein’s Terns Pharmaceuticals TERN Stock Holding History

AllianceBernstein’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.7M	Sell	1,032,679 -255,400	-20%	-$10.5M	0.01%	656
2025 Q4	$52M	Buy	1,288,079 +1,195,179	+1,287%	+$27.6M	0.02%	614
2025 Q3	$698K	Hold	92,900	–	–	﹤0.01%	2512
2025 Q2	$347K	Buy	92,900 +28,800	+45%	+$89.9K	﹤0.01%	2844
2025 Q1	$177K	Sell	64,100 -298,259	-82%	-$1.22M	﹤0.01%	2955
2024 Q4	$2.01M	Buy	362,359 +117,783	+48%	+$798K	﹤0.01%	1956
2024 Q3	$2.04M	Sell	244,576 -53,488	-18%	-$440K	﹤0.01%	1958
2024 Q2	$2.03M	Buy	298,064 +278,854	+1,452%	+$1.69M	﹤0.01%	1945
2024 Q1	$126K	Sell	19,210 -6,740	-26%	-$44K	﹤0.01%	3002
2023 Q4	$168K	Hold	25,950	–	–	﹤0.01%	3008
2023 Q3	$131K	Buy	25,950 +5,230	+25%	+$33.2K	﹤0.01%	3030
2023 Q2	$181K	Buy	+20,720	New	+$241K	﹤0.01%	3004

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

AllianceBernstein's TERN Position: Q1 2026 in Review

AllianceBernstein reduced its Terns Pharmaceuticals (TERN) stake by 20% in Q1 2026, selling an estimated $10.5M and leaving 1,032,679 shares worth $41.7M. The position accounts for 0.01% of the portfolio, ranked #656.

AllianceBernstein first reported a position in TERN in Q2 2023 and has held it in 12 quarters since. The position peaked at $52M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

AllianceBernstein held 1,032,679 shares of Terns Pharmaceuticals worth $41.7M as of Q1 2026.
AllianceBernstein sold 255,400 Terns Pharmaceuticals shares in Q1 2026, an estimated $10.5M.
Terns Pharmaceuticals made up 0.01% of AllianceBernstein's portfolio in Q1 2026, its #656 holding.
AllianceBernstein first reported a position in Terns Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
AllianceBernstein's Terns Pharmaceuticals position peaked at $52M in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.